authorized for use against the SARS-CoV-2 virus.The WHO issued its emergency use listing for the Sinopharm vaccine on May 7, 2021, some 4 months after China’s National Medical Products Administration authorized it on December 31, 2020.
A further 42 countries, including Hungary, Venezuela, and Sri Lanka, have approved the vaccine. However, the European Medicines Agency (EMA) has not yet reviewed it for use in the European Union.Sinopharm and the BBIBP opted to use a well-established technology to develop their COVID-19 vaccine.
The two-dose vaccine incorporates inactivated virus to stimulate an immune response.The Sinopharm vaccine contains SARS-CoV-2 that has undergone treatment with a chemical called beta-propiolactone.